ACXP
What one share of Acurx Pharmaceuticals holds
Pharmaceutical Preparations
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections.
Acurx Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.78 |
|---|---|
| Cash and investments | $2.28 |
| Book value | $1.74 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$14.86 | — | −$10.83 | — | $8.73 |
| 2021 | — | −$29.87 | — | −$11.75 | — | $24.30 |
| 2022 | — | −$22.36 | — | −$13.95 | — | $12.58 |
| 2023 | — | −$23.01 | — | −$15.47 | — | $6.45 |
| 2024 | — | −$17.45 | — | −$12.85 | — | $0.72 |
| 2025 | — | −$5.32 | — | −$4.53 | — | $2.24 |